129 related articles for article (PubMed ID: 22531000)
1. The N-terminal region of CXCL11 as structural template for CXCR3 molecular recognition: synthesis, conformational analysis, and binding studies.
Palladino P; Portella L; Colonna G; Raucci R; Saviano G; Rossi F; Napolitano M; Scala S; Castello G; Costantini S
Chem Biol Drug Des; 2012 Aug; 80(2):254-65. PubMed ID: 22531000
[TBL] [Abstract][Full Text] [Related]
2. Modelling of the membrane receptor CXCR3 and its complexes with CXCL9, CXCL10 and CXCL11 chemokines: putative target for new drug design.
Trotta T; Costantini S; Colonna G
Mol Immunol; 2009 Dec; 47(2-3):332-9. PubMed ID: 19800124
[TBL] [Abstract][Full Text] [Related]
3. Conformational analysis of the human chemokine receptor CXCR3.
Raucci R; Polo A; Budillon A; Colonna G; Costantini S
Mol Immunol; 2017 Dec; 92():76-86. PubMed ID: 29054054
[TBL] [Abstract][Full Text] [Related]
4. Molecular characterization of the chemokine receptor CXCR3: evidence for the involvement of distinct extracellular domains in a multi-step model of ligand binding and receptor activation.
Xanthou G; Williams TJ; Pease JE
Eur J Immunol; 2003 Oct; 33(10):2927-36. PubMed ID: 14515277
[TBL] [Abstract][Full Text] [Related]
5. Review: The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity--a tale of conflict and conundrum.
Müller M; Carter S; Hofer MJ; Campbell IL
Neuropathol Appl Neurobiol; 2010 Aug; 36(5):368-87. PubMed ID: 20487305
[TBL] [Abstract][Full Text] [Related]
6. CCR3 functional responses are regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11.
Xanthou G; Duchesnes CE; Williams TJ; Pease JE
Eur J Immunol; 2003 Aug; 33(8):2241-50. PubMed ID: 12884299
[TBL] [Abstract][Full Text] [Related]
7. Common structural interactions between the receptors CXCR3, CXCR4 and CXCR7 complexed with their natural ligands, CXCL11 and CXCL12, by a modeling approach.
Costantini S; Raucci R; De Vero T; Castello G; Colonna G
Cytokine; 2013 Oct; 64(1):316-21. PubMed ID: 23773308
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist.
Heise CE; Pahuja A; Hudson SC; Mistry MS; Putnam AL; Gross MM; Gottlieb PA; Wade WS; Kiankarimi M; Schwarz D; Crowe P; Zlotnik A; Alleva DG
J Pharmacol Exp Ther; 2005 Jun; 313(3):1263-71. PubMed ID: 15761110
[TBL] [Abstract][Full Text] [Related]
9. Serum chemokine receptor CXCR3 ligands are associated with progression, organ dysfunction and complications of chronic liver diseases.
Tacke F; Zimmermann HW; Berres ML; Trautwein C; Wasmuth HE
Liver Int; 2011 Jul; 31(6):840-9. PubMed ID: 21645215
[TBL] [Abstract][Full Text] [Related]
10. Computational Study of C-X-C Chemokine Receptor (CXCR)3 Binding with Its Natural Agonists Chemokine (C-X-C Motif) Ligand (CXCL)9, 10 and 11 and with Synthetic Antagonists: Insights of Receptor Activation towards Drug Design for Vitiligo.
Aguilera-Durán G; Romo-Mancillas A
Molecules; 2020 Sep; 25(19):. PubMed ID: 32992956
[TBL] [Abstract][Full Text] [Related]
11. Synergistic induction of CXCL9 and CXCL11 by Toll-like receptor ligands and interferon-gamma in fibroblasts correlates with elevated levels of CXCR3 ligands in septic arthritis synovial fluids.
Proost P; Verpoest S; Van de Borne K; Schutyser E; Struyf S; Put W; Ronsse I; Grillet B; Opdenakker G; Van Damme J
J Leukoc Biol; 2004 May; 75(5):777-84. PubMed ID: 14996826
[TBL] [Abstract][Full Text] [Related]
12. Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function.
Colvin RA; Campanella GS; Sun J; Luster AD
J Biol Chem; 2004 Jul; 279(29):30219-27. PubMed ID: 15150261
[TBL] [Abstract][Full Text] [Related]
13. NMR structure of CXCR3 binding chemokine CXCL11 (ITAC).
Booth V; Clark-Lewis I; Sykes BD
Protein Sci; 2004 Aug; 13(8):2022-8. PubMed ID: 15273303
[TBL] [Abstract][Full Text] [Related]
14. CXCR3/ligands are significantly involved in the tumorigenesis of basal cell carcinomas.
Lo BK; Yu M; Zloty D; Cowan B; Shapiro J; McElwee KJ
Am J Pathol; 2010 May; 176(5):2435-46. PubMed ID: 20228225
[TBL] [Abstract][Full Text] [Related]
15. Small molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3.
Nedjai B; Li H; Stroke IL; Wise EL; Webb ML; Merritt JR; Henderson I; Klon AE; Cole AG; Horuk R; Vaidehi N; Pease JE
Br J Pharmacol; 2012 Jun; 166(3):912-23. PubMed ID: 21895630
[TBL] [Abstract][Full Text] [Related]
16. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy.
Tokunaga R; Zhang W; Naseem M; Puccini A; Berger MD; Soni S; McSkane M; Baba H; Lenz HJ
Cancer Treat Rev; 2018 Feb; 63():40-47. PubMed ID: 29207310
[TBL] [Abstract][Full Text] [Related]
17. Identification of overlapping but differential binding sites for the high-affinity CXCR3 antagonists NBI-74330 and VUF11211.
Scholten DJ; Roumen L; Wijtmans M; Verkade-Vreeker MC; Custers H; Lai M; de Hooge D; Canals M; de Esch IJ; Smit MJ; de Graaf C; Leurs R
Mol Pharmacol; 2014 Jan; 85(1):116-26. PubMed ID: 24174496
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of the CXCR3 ligands in chronic hepatitis C virus (HCV) infection and their modulation by HCV in vitro.
Helbig KJ; Ruszkiewicz A; Lanford RE; Berzsenyi MD; Harley HA; McColl SR; Beard MR
J Virol; 2009 Jan; 83(2):836-46. PubMed ID: 18987152
[TBL] [Abstract][Full Text] [Related]
19. Label-free impedance responses of endogenous and synthetic chemokine receptor CXCR3 agonists correlate with Gi-protein pathway activation.
Watts AO; Scholten DJ; Heitman LH; Vischer HF; Leurs R
Biochem Biophys Res Commun; 2012 Mar; 419(2):412-8. PubMed ID: 22349504
[TBL] [Abstract][Full Text] [Related]
20. Elevated serum levels of the CXCR3 chemokine ITAC are associated with the development of transplant coronary artery disease.
Kao J; Kobashigawa J; Fishbein MC; MacLellan WR; Burdick MD; Belperio JA; Strieter RM
Circulation; 2003 Apr; 107(15):1958-61. PubMed ID: 12695288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
